Multichannel
Building capacity in digital
The new era of digital-first engagement demands new approaches to scaling by harnessing technology, seeing content creation as collaborative and cultivating a startup culture
More Articles
Access and Evidence
Bringing innovation to rare disease patients in Europe
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Access and Evidence
#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021
Clinical
Trial site management in the post pandemic era
The impacts of 2020 on trials are causing pharma to consider a new direction for trial sites, taking them closer to the patient
Patients and Medical
Better research through patient insights
AstraZeneca’s innovations in chronic kidney disease are pointing the way to new ways of involving patients and RWE to drive new insights and better outcomes
Clinical
Broadening participation in clinical trials: A win for all
Broader and deeper outreach, along with RWE, are some of the methods pharma is using to widen trials participation
Commercial
Blended and augmented: Reimagining the role of the rep
The events of 2020 have compelled pharma to reimagine the role of the rep to better adapt to the new rules of engagement
Commercial
Uncorking the compliance bottlenecks in digital
The sudden demand for digital content this year has created serious compliance bottlenecks that pharma is racing to overcome with new processes and technology
Clinical
Maimah Karmo: Surviving, fighting, winning
The Tigerlily Foundation President and Founder is more hopeful than ever that she can help pharma give Black women the representation they deserve in trials and beyond
Medical
COVID-19: A data challenge and a catalyst for new insights
The healthcare ecosystem has demonstrated its ability to share data to uncover new insights this year but there is more to be done, says Nigel Hughes, scientific director at Epidemiology, Janssen R&D